MarketCap
Facebook
X
TelegramAnnual report 2024
added 12-13-2025
Nymox Pharmaceutical Corporation Total Shareholders Equity 2011-2025 | NYMX
Annual Total Shareholders Equity Nymox Pharmaceutical Corporation
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | -506 K | 2.14 M | 3.45 M | 7 M | -1.25 M | -241 K | -2.35 M | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 7 M | -2.35 M | 1.18 M |
Quarterly Total Shareholders Equity Nymox Pharmaceutical Corporation
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | -1.39 M | -506 K | 1.58 M | 4.71 M | -12 K | 2.14 M | 38.4 M | -1.06 M | 1.44 M | 3.45 M | 5.65 M | 7.56 M | 10.1 M | 7 M | 3.93 M | 3.55 M | -1.04 M | -1.25 M | - | - | - | -241 K | - | - | - | -2.35 M | - | - | - | -3.78 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 38.4 M | -3.78 M | 3.71 M |
Total Shareholders Equity of other stocks in the Biotechnology industry
| Issuer | Total Shareholders Equity | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
ARCA biopharma
ABIO
|
382 M | - | 1052.0 % | $ 415 M |  USA |
 |
Amphastar Pharmaceuticals
AMPH
|
732 M | $ 25.27 | -2.43 % | $ 1.22 B | USA |
 |
MorphoSys AG
MOR
|
621 M | - | 2.43 % | $ 254 M |  Germany |
 |
Alpine Immune Sciences
ALPN
|
179 M | - | - | $ 2.17 B | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
106 M | $ 4.75 | 1.61 % | $ 788 M |  Canada |
 |
Aclaris Therapeutics
ACRS
|
156 M | $ 3.26 | -3.12 % | $ 252 M | USA |
 |
AlloVir
ALVR
|
113 M | - | 4.14 % | $ 49.1 M | USA |
 |
Acasti Pharma
ACST
|
66.6 M | - | 4.01 % | $ 150 M | Canada |
 |
Adaptimmune Therapeutics plc
ADAP
|
39.5 M | - | -15.15 % | $ 60.3 M |  Britain |
 |
Ampio Pharmaceuticals
AMPE
|
3.36 M | - | -11.43 % | $ 502 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
518 M | - | - | $ 1.01 B | USA |
 |
Kamada Ltd.
KMDA
|
179 M | $ 7.03 | 0.14 % | $ 260 M |  Israel |
 |
Ascendis Pharma A/S
ASND
|
884 M | $ 220.27 | 4.81 % | $ 5 B |  Danmark |
 |
Albireo Pharma
ALBO
|
176 M | - | -0.23 % | $ 916 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-1.1 M | - | - | $ 7.46 M | Israel |
 |
Enlivex Therapeutics Ltd.
ENLV
|
23.6 M | $ 0.91 | -5.01 % | $ 18.7 M | Israel |
 |
Can-Fite BioPharma Ltd.
CANF
|
5.44 M | $ 0.28 | -2.28 % | $ 609 M | Israel |
 |
Alterity Therapeutics Limited
ATHE
|
35.5 M | $ 3.3 | -3.51 % | $ 7.94 B |  Australia |
 |
AstraZeneca PLC
AZN
|
15.6 B | $ 89.78 | -0.57 % | $ 96.9 B | Britain |
 |
Midatech Pharma plc
MTP
|
6.72 M | - | -18.52 % | $ 27.3 M | Britain |
 |
Anika Therapeutics
ANIK
|
212 M | $ 9.57 | 0.84 % | $ 140 M | USA |
 |
Brickell Biotech
BBI
|
9.93 M | - | -5.38 % | $ 6.06 M | USA |
 |
BeiGene, Ltd.
BGNE
|
3.33 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Bellicum Pharmaceuticals
BLCM
|
2.02 M | - | -9.72 % | $ 5.89 M | USA |
 |
Berkeley Lights
BLI
|
142 M | - | -7.31 % | $ 87 M | USA |
 |
Benitec Biopharma
BNTC
|
97.3 M | $ 12.05 | -7.06 % | $ 496 M | USA |
 |
Aytu BioScience
AYTU
|
19 M | $ 2.34 | 2.59 % | $ 14.7 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
673 M | - | -6.81 % | $ 3.04 B | USA |
 |
Aptorum Group Limited
APM
|
21.1 M | $ 1.29 | -3.01 % | $ 7.03 M |  China |
 |
Biophytis SA
BPTS
|
2.27 M | - | -13.47 % | $ 169 M |  France |
 |
Baudax Bio
BXRX
|
-24.2 M | - | 0.59 % | $ 63 K | USA |
 |
Avenue Therapeutics
ATXI
|
2.8 M | - | -52.27 % | $ 4.45 M | USA |
 |
Catalyst Biosciences
CBIO
|
-15.8 M | $ 14.01 | -8.49 % | $ 922 M | USA |
 |
ChromaDex Corporation
CDXC
|
46.1 M | - | -0.88 % | $ 598 M | USA |
 |
Axon Enterprise
AXON
|
2.33 B | $ 566.18 | -2.56 % | $ 42.9 B | USA |
 |
Cerus Corporation
CERS
|
56.1 M | $ 2.16 | 0.47 % | $ 399 M | USA |
 |
Checkpoint Therapeutics
CKPT
|
-12.6 M | - | - | $ 169 M | USA |
 |
Caladrius Biosciences
CLBS
|
29.6 M | - | -16.75 % | $ 25.8 M | USA |
 |
Clovis Oncology
CLVS
|
-279 M | - | -7.23 % | $ 13 M | USA |
 |
Biogen
BIIB
|
16.7 B | $ 174.42 | 1.11 % | $ 25.4 B | USA |
 |
BioVie
BIVI
|
19 M | $ 1.42 | -5.96 % | $ 2.1 M | USA |
 |
Celldex Therapeutics
CLDX
|
747 M | $ 27.36 | -2.09 % | $ 1.76 M | USA |
 |
Cortexyme
CRTX
|
85.1 M | - | -1.05 % | $ 67.1 M | USA |
 |
Cellectar Biosciences
CLRB
|
-15.2 M | $ 3.63 | -3.97 % | $ 44.4 M | USA |
 |
Deciphera Pharmaceuticals
DCPH
|
351 M | - | - | $ 2.18 B | USA |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
-739 M | $ 11.54 | 0.87 % | $ 746 M | USA |